FINWIRES · TerminalLIVE
FINWIRES

Hong Kong Stocks Edge Lower as U.S.-Iran Talks Stall; CITIC Securities Gains on Profit Jump

By

Hong Kong stocks ended little changed Monday as U.S.-Iran talks stalled, heightening concerns over potential disruptions to energy flows.

The Hang Seng Index fell 52.42 points to end marginally lower at 25,925.65, while the Hang Seng China Enterprises Index dropped 19.30 points to 8,756.32.

U.S. President Donald Trump scrapped plans to send envoys to Islamabad for weekend talks, signaling a pause in diplomatic efforts.

He said Sunday Iran could call if it wants to negotiate an end to the conflict, while insisting it must not possess nuclear weapons, after Tehran urged the removal of obstacles to a deal, including the U.S. blockade of its ports.

Sentiment was partially supported after an Axios report said Iran may prioritize reopening the strait while postponing nuclear negotiations.

Meanwhile, China's industrial profits accelerated in March, marking their fastest growth in six months.

Profits rose 15.8% year on year, up from a 15.2% increase in the January-February period, according to data from the National Bureau of Statistics released Monday.

In corporate news, CITIC Securities (HKG:6030, SHA:600030) closed nearly 2% higher after reporting a 55% growth in first-quarter profit.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA